Company Overview

Sonoma Pharmaceuticals, Inc. is a U.S.-based specialty healthcare company focused on developing and commercializing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, oral care, animal health, and infection prevention applications. The company operates within the biotechnology, medical device, and specialty pharmaceutical industries, with products marketed for both prescription and over-the-counter use. Sonoma’s core technology platform is based on its patented Microcyn® technology, which is designed to produce stabilized HOCl solutions intended to reduce microbial contamination and support tissue care without relying on traditional antibiotics.

The company’s primary revenue drivers include sales of advanced wound care products, dermatology therapies, and licensing or distribution agreements with international commercial partners. Sonoma serves healthcare providers, hospitals, consumers, and veterinary markets across multiple geographies. The company traces its origins to Oculus Innovative Sciences, founded in 1999, and later rebranded as Sonoma Pharmaceuticals to reflect its broader healthcare commercialization strategy. Its positioning centers on non-antibiotic anti-infective technologies and diversified global distribution relationships.

Business Operations

Sonoma Pharmaceuticals generates revenue through product sales, licensing arrangements, and strategic distribution partnerships. Its operations are organized around several healthcare categories, including Wound Care, Dermatology, Eye Care, Oral Care, and Animal Health products. The company commercializes products under proprietary and partner-branded labels, with formulations intended for skin treatment, scar management, sinus and oral hygiene, and infection control applications. Sonoma maintains intellectual property associated with stabilized HOCl formulations and manufacturing processes.

The company operates domestically in the United States while maintaining international commercial activities across Europe, Asia, Latin America, and the Middle East through distributors and regional partners. Sonoma has historically relied on partnerships rather than large direct sales infrastructures in many overseas markets. The company also controls manufacturing capabilities associated with its HOCl technology platform and has entered into agreements with healthcare distributors and medical product companies to expand market access. Public filings indicate ongoing collaboration-oriented commercialization strategies rather than large-scale vertically integrated operations.

Strategic Position & Investments

Sonoma Pharmaceuticals’ strategic direction has focused on expanding adoption of its HOCl-based technologies across medical and consumer healthcare categories. The company has pursued growth through new product launches, geographic expansion, regulatory clearances, and commercial partnerships. Management has emphasized the potential role of non-antibiotic antimicrobial products in wound management and skin care markets, particularly amid broader healthcare interest in antimicrobial stewardship and alternatives to conventional antibiotics.

The company has also invested in broadening its dermatology and aesthetic care portfolio, including products aimed at scar reduction, acne treatment, and post-procedure skin care. Sonoma’s strategy has included licensing arrangements and distribution agreements rather than large acquisition-driven expansion. Public disclosures show continued investment in proprietary formulations, brand development, and international commercialization channels. Data regarding major acquisition activity is limited based on available public sources, and the company has historically remained relatively focused on organic product portfolio development and partnership-led market penetration.

Geographic Footprint

Sonoma Pharmaceuticals is headquartered in Boulder, Colorado, with operational and commercial activities extending across multiple international regions. The company maintains a market presence in the United States, Europe, Asia, Latin America, and parts of the Middle East through direct operations and third-party distribution networks. International revenue has historically represented a meaningful component of the company’s business mix.

The company’s products have been commercialized in countries including the United States, Mexico, China, South Korea, and several European markets. Sonoma’s international strategy has largely depended on regional licensing and distribution agreements that allow localized commercialization of its HOCl-based products. Public company filings indicate continued efforts to diversify geographic revenue streams and expand regulatory approvals outside the U.S. market.

Leadership & Governance

Sonoma Pharmaceuticals has operated under a leadership structure focused on commercialization efficiency, product development, and international partnerships. The company’s governance framework includes executive management and a board of directors overseeing operational execution, regulatory compliance, and strategic growth initiatives. Leadership communications have consistently emphasized expanding the commercial reach of the company’s stabilized HOCl technology platform while maintaining disciplined operating expenditures.

Key executives and leadership figures include:

• Amy Trombly – Chief Executive Officer
• Bob Miller – Chief Financial Officer
• Brian Andrews – Senior Vice President, Sales
• Ronald P. Pelligrino – Chairman of the Board

The company was originally founded as Oculus Innovative Sciences and later evolved into Sonoma Pharmaceuticals as part of a broader strategic repositioning toward diversified healthcare and consumer wellness applications. Leadership strategy has emphasized international distribution partnerships, portfolio expansion, and the advancement of non-antibiotic antimicrobial technologies.